{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:07:18Z","timestamp":1787800038872,"version":"build-2784847793"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T00:00:00Z","timestamp":1570579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.01033","type":"journal-article","created":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T16:08:08Z","timestamp":1570637288000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma"],"prefix":"10.3389","volume":"9","author":[{"given":"Emilien","family":"Billon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Walz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Brunelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Thomassin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naji","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Guerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Vicier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slimane","family":"Dermeche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Albiges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Tantot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soazig","family":"Nenan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"Pignot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwena\u00eblle","family":"Gravis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,10,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer."},{"key":"B2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.semcancer.2012.06.004","article-title":"Current and future systemic treatments for renal cell carcinoma","volume":"23","author":"Fisher","year":"2013","journal-title":"Semin Cancer Biol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","article-title":"Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial","volume":"14","author":"Motzer","year":"2013","journal-title":"Lancet Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"crossref","unstructured":"ChoueiriTK\n            MotzerRJ\n            CampbellMT\n            AlekseevBY\n            UemuraM\n            KollmannsbergerCK\n          Subgroup Analysis from JAVELIN Renal 101: Outcomes for Avelumab Plus Axitinib (A + Ax) versus Sunitinib (S) in Advanced Renal Cell Carcinoma (aRCC)2019","DOI":"10.1200\/JCO.2019.37.7_suppl.544"},{"key":"B9","unstructured":"PowlesT\n            PlimackER\n            StusV\n            GafanovRA\n            HawkinsRE\n            NosovD\n          28246756Pembrolizumab (pembro) Plus Axitinib (axi) versus Sunitinib as First-Line Therapy for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC): Phase III KEYNOTE-426 Study2019"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1111\/j.1755-148X.2012.00997.x","article-title":"Revised classification\/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference","volume":"25","author":"Ezzedine","year":"2012","journal-title":"Pigment Cell Melanoma Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J Clin Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e1375642","DOI":"10.1080\/2162402X.2017.1375642","article-title":"Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer","volume":"7","author":"Kim","year":"2017","journal-title":"Oncoimmunology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejca.2016.12.038","article-title":"Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity","volume":"75","author":"Gutzmer","year":"2017","journal-title":"Eur J Cancer Oxf Engl."},{"key":"B17","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death\u22121 pathway inhibitors among patients with non\u2013small-cell lung cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J Clin Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/1756-185X.13444","article-title":"Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy","volume":"22","author":"Liew","year":"2019","journal-title":"Int J Rheum Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jdermsci.2016.01.006","article-title":"HLA-DQB1 gene polymorphisms and non-segmental vitiligo: a case-control study in the Korean population","volume":"82","author":"Moon","year":"2016","journal-title":"J Dermatol Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2217\/imt-2017-0020","article-title":"A case of fulminant Type 1 diabetes following anti-PD1 immunotherapy in a genetically susceptible patient","volume":"9","author":"Ara\u00fajo","year":"2017","journal-title":"Immunotherapy."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1158\/2159-8290.CD-NB2018-104","article-title":"MHC expression predicts checkpoint blockade response","volume":"8","author":"Caruso","year":"2018","journal-title":"Cancer Discov."},{"key":"B26","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic hodgkin lymphoma","volume":"36","author":"Roemer","year":"2018","journal-title":"J Clin Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/iju.13590","article-title":"Case of complete response to neoadjuvant therapy using nivolumab in a patient with metastatic renal cell carcinoma","volume":"25","author":"Ikarashi","year":"2018","journal-title":"Int J Urol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.eucr.2018.02.016","article-title":"What is the role of nephrectomy following complete response to checkpoint inhibitors?","volume":"18","author":"Woldu","year":"2018","journal-title":"Urol Case Rep."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1093\/annonc\/mdy041","article-title":"Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases","volume":"29","author":"Vokes","year":"2018","journal-title":"Ann Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1186\/s12885-018-4819-2","article-title":"Efficacy of anti-PD-1\/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)","volume":"18","author":"Tachihara","year":"2018","journal-title":"BMC Cancer."},{"key":"B32","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1158\/1078-0432.CCR-18-0793","article-title":"Long-term survival in patients responding to anti\u2013PD-1\/PD-L1 therapy and disease outcome upon treatment discontinuation","volume":"25","author":"Gauci","year":"2019","journal-title":"Clin Cancer Res."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.01033\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T16:08:12Z","timestamp":1570637292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.01033\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,9]]},"references-count":32,"alternative-id":["10.3389\/fonc.2019.01033"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.01033","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,9]]},"article-number":"1033"}}